Content Type: Article

  • Long-term commercial leases – a labyrinth of formal requirements

    Long-term commercial leases – a labyrinth of formal requirements

    ARTICLE / CLIENT ALERT

    Long-term commercial leases – a labyrinth of formal requirements

    October 21, 2024

    Read time: 9 min

    Key takeaways
    Overview

    The statutory written form requirement for long-term commercial leases has always been criticised by many practitioners. This makes expectations all the greater when – as recently – a change is actually announced. In this article, Thomas Beisken and Carolin Irla discuss the changes.

    In depth

    1. Gesetzliche Schriftform und elektronische Form – die bisherige Rechtslage

    Der Begriff des Schriftformerfordernisses ist bei näherer Betrachtung unpräzise. Die Einhaltung der Schriftform stellt auch derzeit kein „Erfordernis“ im Sinne einer Wirksamkeitsvoraussetzung dar. § 550 S. 1 BGB bestimmt lediglich, dass ein Mietvertrag, der für längere Zeit als ein Jahr nicht in schriftlicher Form geschlossen wird, für unbestimmte Zeit gilt (d.h. ordentlich kündbar ist). Die Rechtsfolge eines Verstoßes gegen § 550 S. 1 BGB besteht folglich nicht in der Unwirksamkeit des Mietvertrages, sondern lediglich in der Kündbarkeit des Mietvertrages vor Ablauf der vereinbarten Festlaufzeit.

    Bislang gilt die gesetzliche Schriftform, d.h. dass der Mietvertrag von dem Aussteller eigenhändig durch Namensunterschrift oder mittels notariell beglaubigten Handzeichens unterzeichnet werden muss, um eine langfristige Bindung sicherzustellen. Damit muss der Mietvertrag grundsätzlich mittels „handschriftlicher“ Unterschrift auf Papier durch beide Parteien unterzeichnet werden.

    Zu der gesetzlichen Schriftform hat sich über die Jahre eine umfangreiche Kasuistik gebildet, die in der Regel auf den Schutzzweck des § 550 BGB zurückzuführen ist. Die Schriftform soll insbesondere den Erwerber schützen, der in den Mietvertag qua Gesetz eintritt („Kauf bricht nicht Miete“) und vor diesem Hintergrund allein anhand des Mietvertrages Kenntnis über dessen wesentlichen Inhalt erlangen können soll. Nach der höchstrichterlichen Rechtsprechung soll § 550 BGB darüber hinaus auch eine Warn- und Beweisfunktion zum Schutz der Mietvertragsparteien gewährleisten.

    Die gesetzliche Schriftform kann nur sehr eingeschränkt auf andere Weise als durch die klassische eigenhändige Unterschrift gewährleistet werden. Die alternativ zulässige elektronische Form (§ 126 Abs. 3 BGB) erfordert eine qualifizierte elektronische Signatur nach § 126a BGB, die sich aufgrund ihrer umständlichen Handhabung in der Praxis bislang nicht durchgesetzt hat. Die bloß eingescannte Unterschrift oder die Unterschrift auf dem Tablet genügt nicht. Die elektronische Signatur muss auf einem qualifizierten Zertifikat beruhen, das von einem „qualifizierten Vertrauensdiensteanbieter“ ausgestellt wird. Dass dieses Vorgehen wenig intuitiv und nicht praxisfreundlich ist, legt schon diese Formulierung nahe.

    2. Textform – die Neuerung nach dem BEG IV

    Das BEG IV sieht vor, dass § 550 BGB im Rahmen von Gewerberaummietverträgen mit der Maßgabe anzuwenden ist, dass ein langfristiger Mietvertrag, der nicht in Textform geschlossen wird, für unbestimmte Zeit gilt. Mit dem Wechsel zur Textform entfällt insbesondere das Erfordernis einer eigenhändigen Unterschrift.

    Für die Wahrung der Textform (§ 126 BGB) sind folgende Voraussetzungen vorgesehen:

    (i) Lesbarkeit der Erklärung: Die Erklärung muss z.B. auf Papier oder auf einem Computerbildschirm lesbar sein. Ausreichend sind auch elektronische Daten, die als solche nicht lesbar sind, aber in Standardformaten (etwa .pdf, .doc, .tiff, .html, .rtf oder .txt) verwendet werden.

    (ii) Nennung der Person des Erklärenden: Im konkreten Fall muss auf Grund der zwischen den Parteien bestehenden Beziehungen die Person des Erklärenden hinreichend erkennbar sein – der Nachname ist damit z.B. nicht stets erforderlich. Eine Unterschrift ist nicht erforderlich; die Nennung ist auch im Text oder Kopfteil möglich.

    (iii) Abgabe auf einem dauerhaften Datenträger: Ein dauerhafter Datenträger ist legaldefiniert als jedes Medium, das es dem Empfänger ermöglicht, eine auf dem Datenträger befindliche, an ihn persönlich gerichtete Erklärung so aufzubewahren oder zu speichern, dass sie ihm während eines für ihren Zweck angemessenen Zeitraums zugänglich ist, und geeignet ist, die Erklärung unverändert wiederzugeben.

    (iv) Erkennbarkeit des Abschlusses der Erklärung: Nach wohl überwiegender Ansicht muss die in Textform abzugebende Erklärung darüber hinaus einen erkennbaren Abschluss (z.B. Grußformel) haben, um sie – in Abgrenzung zum bloßen Entwurf – als rechtlich bindend und vollständig erkennen zu können.

    Erneut viel „juristischer Kauderwelsch“. Übersetzt heißt all dies, dass für den Abschluss von langfristigen Gewerberaummietverträgen und Änderungen von solchen zukünftig auch per E-Mail, Fax oder SMS übermittelte Erklärungen ausreichend sein werden. Auch Nachrichten über Messenger-Dienste wie WhatsApp werden überwiegend für ausreichend gehalten. Dies ist allerdings (noch) umstritten.

    Die zum 1. Januar 2025 in Kraft tretende formale Erleichterung darf jedoch nicht zu der Annahme führen, dass zukünftig nicht mehr alle wesentlichen Bedingungen des Mietverhältnisses ordnungsgemäß zu dokumentieren sind. Werden die wesentlichen Bedingungen des Mietverhältnisses zukünftig nicht wenigstens in Textform vereinbart, gilt weiterhin, dass der betreffende Mietvertrag vorzeitig kündbar sein wird. Der Mietvertrag nebst Anlagen ist daher weiterhin sorgfältig zu entwerfen und auszufertigen.

    3. Die gewillkürte Schriftform – eine gleichwertige Alternative zur gesetzlichen Schriftform?

    Von der gesetzlichen Schriftform (§ 126 BGB) weiter zu unterscheiden ist die vertraglich vereinbarte (gewillkürte) Schriftform (§ 127 BGB). Parteien können die Schriftform insofern durch Rechtsgeschäft bestimmen. Dies ist oft der Fall bei Verträgen, bei denen – anders als bei langfristigen Mietverträge – das Gesetz kein bestimmtes Formerfordernis vorsieht. Im Zweifel, d.h. wenn die Parteien nicht etwas anderes vereinbart haben, gelten für die gewillkürte Schriftform die gleichen Vorgaben wie für die gesetzliche Schriftform, allerdings mildert § 127 Abs. 2 BGB die Formanforderungen für die gewillkürte Schriftform – erneut vorbehaltlich eines entgegenstehenden Parteiwillens – ab. Zur Wahrung der gewillkürten Schriftform genügt danach grundsätzlich die telekommunikative Übermittlung und bei einem Vertrag der Briefwechsel.

    Die telekommunikative Übermittlung erlaubt etwa die Übersendung der Erklärung durch Telefax oder einfache E-Mail (d.h. auch ohne eingescannte Unterschrift). Erforderlich ist, dass die Erklärung dauerhaft gespeichert werden kann, sodass zumindest die Voraussetzungen der Textform erfüllt sein müssen. Im Falle der Einbeziehung der telekommunikativen Übermittlung entsteht insofern regelmäßig ein Gleichlauf von Text- und gewillkürter Schriftform. Es steht den Parteien im Rahmen der gewillkürten Schriftform allerdings frei, beispielsweise strengere Anforderungen für bestimmte Aspekte (Änderungen der Miete etc.) festzulegen.

    Im Rahmen der gewillkürten Schriftform genügt ferner (wiederum vorbehaltlich eines entgegenstehenden Parteiwillens), anders als im Rahmen der gesetzlichen Schriftform, ein Briefwechsel, bei dem nicht die Erklärungen beider Seiten in einer Urkunde zusammengefasst sind.

    Bei der gewillkürten Schriftform sollten zudem die Rechtsfolgen eines Verstoßes explizit geregelt werden: Erlaubt die Missachtung der gewillkürten Schriftform „nur“ die ordentliche Kündigung oder hat sie die Unwirksamkeit des Vertrages zur Folge? Grundsätzlich vermutet das Gesetz, dass im Zweifelsfall der Vereinbarung der Schriftform konstitutive Bedeutung für die Wirksamkeit des Vertrages zukommt.

    Ob die gewillkürte der gesetzlichen Schriftform „gleichwertig“ ist, hängt von der Formulierung der Schriftformklausel im Einzelfall ab. Inwieweit die Parteien über die Textform hinausgehen wollen, dürfte von Faktoren wie der wirtschaftlichen Bedeutung des Mietvertrages und den praktischen Bedürfnisse der Parteien abhängen. “One-Size-Fits-All” greift bei Schriftformklauseln zu kurz. Denkbar wäre etwa, dass die Parteien Abreden über bestimmte Kommunikationswege (z.B. E-Mail und Messenger-Dienste) ausschließen, zugleich aber zur Vereinfachung des Unterschriftenprozesses den Austausch über Signaturplattformen wie z.B. DocuSign als formwirksam vereinbaren.

    4. Macht die Wahl der Form einen Unterschied in einem Prozess?

    In einem Rechtsstreit können Verträge in Schriftform – gleich ob gesetzliche oder gewillkürte – uneingeschränkt zur Beweisführung genutzt werden. Der Beweiswert von Erklärungen in Textform wird dagegen grundsätzlich als eher gering eingestuft, da sich der Erklärende nicht durch eine Unterschrift – und damit eine verlässliche Identifizierung – zu der Erklärung bekennen muss. Der Textform kommt insofern eher eine Dokumentations- als Beweisfunktion zu.

    Insbesondere im Hinblick auf ausbleibende Mietzahlungen ist regelmäßig der Urkundenprozess das Mittel der Wahl. Da elektronische Dokumente keine Urkunden im Sinne der Zivilprozessordnung, sondern sog. Augenscheinsobjekte sind, können diese selbst nicht Gegenstand des Urkundenprozesses sein. Sie können lediglich als Ausdruck zum Gegenstand des Urkundenprozesses gemacht werden, wobei jedoch zu beachten ist, dass das Fälschungsrisiko den Beweiswert schmälert. Wird die Echtheit des Ausdrucks bestritten und kommt es auf die Vorlage des elektronischen Dokuments selbst an, kann dieser Augenscheinsbeweis im Urkundenprozess nicht angetreten werden.

    Ergänzend ist im Hinblick auf die Beweislast zu berücksichtigen, dass derjenige, der aus dem formbedürftigen Rechtsgeschäft Rechte herleiten will, die Einhaltung des Formerfordernisses (formwirksame Abgabe und Zugang der Erklärung) beweisen muss. Der Zugang einer E-Mail oder SMS ist im Regelfall nicht gerichtsfest nachweisbar.

    5. Gilt die Textform auch für langfristige Gewerberaummietverträge, die vor dem 1. Januar 2025 abgeschlossen wurden?

    Für vor dem Inkrafttreten des BEG IV abgeschlossene Gewerberaummietverträge gilt eine Übergangsfrist von 12 Monaten. Während dieser 12 Monate kann die ordentliche Kündigung wegen eines Schriftformverstoßes noch wirksam erklärt werden. Wird der Mietvertrag (nach Inkrafttreten der Gesetzesänderung) geändert, ist die neue Rechtslage auf den Mietvertrag ohne Übergangsfrist vollumfänglich anwendbar. Maßgeblich ist dann – vorbehaltlich abweichender Vereinbarungen – allein, ob die Textform eingehalten wurde.

    6. Fazit

    Die neu eingeführte Textform für langfristige Gewerberaummietverträge erscheint auf den ersten Blick als praxistaugliche Vereinfachung, jedenfalls dergestalt, dass man die Mietvertragsurkunde zur Unterzeichnung nicht mehr zeitaufwendig hin- und herschicken muss. Bei genauem Hinsehen wird jedoch schnell klar, dass bei der Vorbereitung eines ordentlichen Gewerberaummietvertrages weiterhin sehr sorgfältig vorgegangen werden muss. Selbiges gilt für die Änderung von Mietverträgen – in Zukunft wohlmöglich durch einen WhatsApp -Chatverlauf. Es wird noch spannend werden, wie in zukünftigen Ankaufsprüfungen die Abwesenheit von WhatsApp-Nebenabreden zu Mietverträgen geprüft werden wird. Angesichts der Gratwanderung zwischen pragmatischer Handhabung, Rechtssicherheit und zuverlässiger Beweisführung wird zukünftig der Formulierungen vertraglicher Schriftformklauseln besondere Aufmerksamkeit zukommen müssen.

    Authors

    Thomas A. Beisken, LL.M.

    Partner

    Düsseldorf

    Carolin Irla

    Associate

    Düsseldorf

    More insights

  • NYDFS Issues Letter Highlighting Cybersecurity Risks of AI

    NYDFS Issues Letter Highlighting Cybersecurity Risks of AI

    ARTICLE / CLIENT ALERT

    NYDFS Issues Letter Highlighting Cybersecurity Risks of AI

    October 18, 2024

    Read time: 5 min

    Key takeaways
    Overview

    On October 16, 2024, the New York State Department of Financial Services (NYDFS) published a letter to covered entities that calls attention to the risks posed by artificial intelligence (AI). This non-binding guidance letter does not impose any new requirements but instead highlights AI-enabled cybersecurity risks to nonpublic information (NPI) and how certain portions of NYDFS’s Part 500 regulations can combat those risks.

    This letter is the latest example of NYDFS focusing on and providing guidance related to AI risks. In July 2024, NYDFS published a similar letter highlighting the risks of AI use in insurance underwriting and pricing. And NYDFS’s efforts are part of a broader focus in New York to encourage responsible AI development, including Governor Kathy Hochul’s focus on AI governance. Below, we summarize the risks NYDFS is concerned about and highlight several key takeaways.

    In depth

    Risks

    The letter addresses four central AI-enabled risks that covered entities need to consider if they want an effective cybersecurity program. Two risks arise from threat actors leveraging AI and two from covered entities’ use of AI.

    Threat Actors Leveraging AI

    • AI-Powered Social Engineering: With publicly accessible tools that can mimic someone’s face, voice, or writing style based on limited samples, it is easier than ever to create deepfake videos, audio, or text that can lead to funds transfer fraud or business email compromise events.
    • AI-Powered Cybersecurity Attacks: NYDFS points out that threat actors can use AI at every point in the attack chain: deploying malware, mining/exfiltrating NPI, and bypassing security controls. Not only does this increase the speed and scale through which cyberattacks can spread, but it also lowers the barrier to entry for cybercriminals interested in launching attacks through AI code development platforms.

    Covered Entities’ Use of AI

    • Training Data, Prompts, and Outputs Include NPI: Developing and deploying AI systems requires a steady flow of training data to build reliable and nondiscriminatory models. This training data can include NPI and, as a result, these systems are significant targets for cyberattacks.
    • Risk of Third-Party Breaches: Noting that no business can hold, manage, and secure the vast amount of data needed, NYDFS highlighted that particular companies like IT managed service providers, hosting services, and similar services are bigger targets because of the role they play in training and deploying AI systems.

    Key Takeaways

    NYDFS indicates five areas where covered entities should use the framework set forth in Part 500 to assess and address the cybersecurity risks arising from AI:

    Conduct Annual Risk Assessments

    Part 500.9 requires covered entities to engage in annual risk assessments, which can be expanded to cover AI threats to the business, the business’s own use of AI, any third-party AI use, and potential cybersecurity vulnerabilities of these AI systems. These risk assessments should inform other phases of the organization’s cybersecurity program, from policies and procedures to tabletop exercises. The process of engaging in a risk assessment can also be a good opportunity for board or senior governing body oversight.

    Establish a Third-Party Due Diligence Process

    Part 500.11 requires covered entities to implement policies and procedures for how covered entities identify, evaluate, and mitigate cybersecurity threats from third-party vendors they contract with. NYDFS notes how these third-party due diligence efforts can include threats from AI use cases, including having additional representations and warranties related to the secure use of NPI. For example, contracts with vendors employing AI systems could include requirements to abide by certain cybersecurity practices like encryption, multifactor authentication (MFA), and event logging.

    Enable MFA for Individuals With Access to NPI

    NYDFS also mentions how MFA using at least two of the three authentication factors (something you know, something you have, something you are) is one of the strongest access control methods. Along with previous MFA guidance from 2021, NYDFS recommends that organizations consider how biometric MFA methods can be spoofed with deepfake technology and adjust policies and procedures to account for those risks.

    Update Cybersecurity Trainings to Include AI Threats

    NYDFS recommends amending employee trainings to address emerging threats and tailoring trainings to employees working with AI systems to ensure they are writing prompts to exclude NPI.

    Maintain a Comprehensive Data Inventory

    Although not required until November 1, 2026, Part 500.13(a) requires covered entities to maintain and update data inventories. As part of that process, data inventories should identify all AI systems in use by the covered entity and prioritize mitigations based on those systems.

    Adding AI considerations onto all Part 500 regulations will require extensive work. For assistance with conducting a risk assessment or analyzing how AI might affect your company’s compliance efforts, please contact the authors of this article or your regular McDermott lawyer.

    Authors

    Katelyn N. Ringrose

    Associate

    Washington, DC

    More insights

  • NY Providers Take Note: New Consent to Payment Laws Effective October 20

    NY Providers Take Note: New Consent to Payment Laws Effective October 20

    ARTICLE / CLIENT ALERT

    NY Providers Take Note: New Consent to Payment Laws Effective October 20

    October 18, 2024

    Read time: 6 min

    Key takeaways
    Overview

    Key Update

    On October 20, 2024, two new laws were scheduled to take effect in New York that would impact how healthcare providers obtain consent to payment and collect payments from patients. On October 21, 2024, the Medical Society of the State of New York (MSSNY) announced that it had received a copy of guidance issued by the New York State Department of Health (DOH) to hospital CEOs that indicates that the implementation of part of the updated law will be put on hold pending further guidance. These laws will affect healthcare providers, particularly those who maintain patients’ credit card information on file, including many digital health providers. Although no regulations or guidance have been issued or proposed to date on how to implement these laws, and therefore significant ambiguities remain, providers who render services to patients located in New York should be aware of these changes and assess their consent and billing processes for compliance.

    Why It Matters

    • Effective October 20, 2024, two new laws will impact how healthcare providers in New York collect payment from patients. Specifically, healthcare providers:
      • Must obtain consent for payment separate from consent to receive healthcare services; such consent to payment cannot be given prior to the patient receiving services and discussing treatment costs.
      • Are prohibited from requiring credit card pre-authorization or requiring a patient’s credit card be kept on file prior to the delivery of “emergency or medically necessary services.”
      • Must notify patients of the risks of using credit cards to pay for healthcare services.
    • Although these laws apply to all healthcare providers in New York, they may particularly impact digital health providers’ payment practices.
    • Significant ambiguities and uncertainties remain regarding the laws, and no guidance has been issued to date.
    • Healthcare providers should assess their current consent and billing processes and determine changes necessary to comply with the laws. They also should develop notifications regarding the risks of paying for medical services with credit cards.
    In depth

    Background

    The two new laws were enacted as part of New York’s fiscal year 2024 – 2025 budget.

    Requirements for Patient Consent to Payment

    NY Public Health Law (PHL) § 18-c provides (1) that a patient’s consent to pay for healthcare services must be obtained separately from the informed consent for such healthcare services, and (2) that consent to payment may only be obtained after the patient has received the applicable services and discussed treatment costs.

    The statute does not expressly state to whom it applies; it refers only to “patients” and not to any category of healthcare providers. It is also unclear whether a patient must provide new consent each time a different service is offered, and whether multiple consents are necessary for a course of treatment. MSSNY and several medical specialty organizations recently sent a letter to the DOH expressing the logistical and operational challenges that the PHL § 18-c requirements pose to medical practices, and urging that the law be revised to allow consent prior to the provision of services. As an apparent result of this outreach, on October 21, 2024, MSSNY announced that it had received a copy of guidance issued by the DOH directed to hospital CEOs that indicates that the implementation of these consent-related changes will be put on hold pending further guidance to be issued by DOH.

    Requirements for Credit Card Payments for Healthcare Services

    NY General Business Law (GBL) § 519-a prohibits hospitals and healthcare providers from (1) requiring credit card pre-authorization and (2) requiring that a credit card be kept on file prior to “providing emergency or medically necessary medical services” to the patient.

    GBL § 519-a’s requirements apply to emergency and “medically necessary” services. The statute does not define “medically necessary,” although the phrase could be read broadly to encompass any service that is not solely for a patient’s convenience or for a cosmetic, experimental, or investigational purpose, or is not reimbursable by insurance. Like PHL § 18-c, the statute does not define “health care providers,” although it can be read to apply to professionals, professional practices, and hospitals.

    GBL § 519-a also requires hospitals and healthcare providers to notify all patients about the risks of paying for medical services with a credit card. Such notification must highlight the fact that by using a credit card to pay for medical services, the patient is foregoing state and federal protections regarding medical debt. The law gives DOH the authority and sole discretion to set requirements for the contents of such notices; DOH has not issued any such requirements or further guidance as of the date of this alert.

    Open Questions and Next Steps for Healthcare Providers

    As described above, significant ambiguities and uncertainties remain regarding PHL § 18-c and GBL § 519-a’s requirements.

    To date, with the exception of the DOH letter noted above, no regulations or guidance has been proposed or issued to help providers understand their obligations under these new laws. In the absence of guidance, it is unclear how New York will enforce the requirements of PHL § 18-c and GBL § 519-a. Nonetheless, the DOH and the New York Attorney General have authority to enforce compliance with the Public Health Law, and the Attorney General has authority to enforce compliance with the General Business Law. Healthcare providers should be aware that penalties exist for noncompliance with both statutes regardless of further regulations or guidance.

    Providers should assess their current consent and billing processes and determine how they may need to change to comply with the new laws. For example, once DOH issues its guidance, providers that utilize a single consent form combining informed consent for services and consent to payment should update their forms to obtain separate consents for treatment and payment, and address other considerations if raised in the DOH guidance. Providers should also take steps to develop patient notifications regarding risks of paying for healthcare services with a credit card, in line with the requirements of GBL § 519-a, while awaiting guidance from DOH on specific requirements for such notices. Providers should assess the impact of these new requirements in conjunction with other requirements, such as those under the federal No Surprises Act, other New York state laws, and payor contracts, which require upfront disclosure of costs to patients and may conflict with certain provisions of these new requirements.

    Please contact the authors or your regular McDermott lawyer with any questions related to these new requirements.

    Authors

    Grayson I. Dimick

    Associate

    Washington, DC

    Amanda Enyeart

    Partner

    Chicago

    Gregory R. Mitchell

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • SEC Fines Director for Failing to Disclose Close Friendship With Senior Executive

    SEC Fines Director for Failing to Disclose Close Friendship With Senior Executive

    ARTICLE / CLIENT ALERT

    SEC Fines Director for Failing to Disclose Close Friendship With Senior Executive

    October 17, 2024

    Read time: 6 min

    Key takeaways
    Overview

    In a novel enforcement action, the US Securities and Exchange Commission (SEC) charged a member of the board of directors of a New-York-Stock-Exchange (NYSE)-listed manufacturer of personal and household products for violating the proxy disclosure rules. According to the SEC, the director stood for election as an “independent” director when he did not qualify as independent due to an undisclosed close friendship with one of the company’s high-ranking executives. The director was personally fined $175,000 and barred from serving as an officer or director of a publicly traded company for five years.

    This case serves as a reminder of one of the primary roles of directors in a publicly traded company: to oversee and monitor senior management on behalf of the stockholders who elect them. This case also highlights the fact that director independence is highly dependent on facts and circumstances and, although public company boards are required by stock exchange rules to assess board member independence annually, the burden is on the individual board member to disclose to the board (so that the board can make its independence determination) relationships with senior management that impair independence.

    In this case, the SEC found that the director not only failed to disclose his personal friendship with the executive, but actively sought to conceal it from the company’s Board of Directors in a breach of the director’s duty of candor under the company’s Code of Conduct. Such breach, in the context of the company’s annual proxy statement disclosure exercise, violated Section 14(a) of the Securities Exchange Act of 1934.

    In depth

    Background

    According to the allegations in the complaint, the individual charged by the SEC was an experienced public company director. After serving as the CEO of the company for 11 years, he served as the non-executive chairman of its Board for four years. He also served as an independent director of two other public companies during the period in question.

    In 2019, the Board made the determination that after the required “cooling off” period from his former executive days had transpired (the director retired as CEO in 2015), nothing precluded him from being classified as an “independent” director since he did not otherwise have a material relationship with the company or its senior management team. As a result, the director stood for reelection at the annual stockholders’ meetings from 2019 to 2023 and was described as an “independent” director candidate.

    However, according to the SEC, the director had a close personal relationship with the executive since 2017. The director and the executive, along with their spouses, regularly vacationed together – both domestically and internationally – from 2020 to 2023, including six trips that spanned eight countries across five continents. During these trips, the director paid for the executive’s first-class airfare and lodging. In all, during the relevant period, the director spent more than $100,000 on travel and vacations for the executive and his spouse. The director did not disclose this relationship to the Board and advised the executive not to tell anyone at the company about their close friendship.

    In addition to the travel, the director also shared with the executive, in violation of his duty of confidentiality, information about a sensitive CEO search process being conducted by the Board, which included the executive’s potential candidacy.

    Takeaways

    The public company governance ecosystem relies on the independence of board members. With certain exceptions, stock exchange rules mandate that public company boards be comprised of a majority of independent directors and major standing board committees (audit, compensation, and nominating/governance) be independent. These stock exchange governance requirements are meant to instill confidence in the investing public that management teams are overseen by board members who, in addition to complying with state law fiduciary duties, avoid relationships with management that could impair their objectivity.

    The SEC action highlights the importance of evaluating independence from multiple perspectives. Under the NYSE rules, no director qualifies as “independent” unless the board of directors affirmatively determines that the director has no material relationship with the listed company. In the words of the NYSE Listed Company Manual, “it is not possible to anticipate, or explicitly to provide for, all circumstances that might signal potential conflicts of interest, or that might bear on the materiality of a director’s relationship to a listed company.” The overriding concern, however, is independence from management. Any relationship between a director and a member of senior management could potentially impair a board member’s impartiality and independence.

    The NYSE Listed Company Manual provides some guidance on the types of relationships that should be considered. For example, “material relationships can include commercial, industrial, banking, consulting, legal, accounting, charitable and familial relationships, among others.” Notably, “friendship” is not called out expressly in the nonexclusive list. And most company “director and officer questionnaires,” which effectively function as the front line of defense in the annual board exercise to determine board member independence, track the NYSE commentary on this point.

    In the aftermath of the enforcement action, boards should consider revising their questionnaires to inquire about meaningfully close personal relationships between directors and senior management. Even once a company solicits the information needed to evaluate disclosure decisions, the SEC action raises difficult line-drawing questions. For instance, would a strong mentoring relationship between a board member and an executive impair independence? Similarly, it is not unusual for directors and executives to maintain some form of social relationship outside the company. Perhaps the SEC’s action will be limited to its facts, particularly given the alleged extensive effort of the director to conceal the relationship. A different fact pattern very well could produce a different outcome.

    The other significant takeaway is the SEC’s decision to pursue an action against the director personally, rather than the issuer, for misleading proxy disclosure. That decision could have been made for any number of reasons (including the active concealment of the relationship by the director), but it signals the SEC’s willingness to pursue, penalize, and bar individual board members. Directors should take note of the SEC’s aggressive posture, and public companies should be wary of future cases that might charge the public company alongside or in place of the director. The SEC has been aggressively pursuing public companies for internal control failures to identify information required for public disclosures.

    More philosophically, this case also reflects the SEC’s willingness to recast stock exchange corporate governance principles as federal securities law disclosure claims.

    While individual directors digest this recent SEC enforcement action, it might be prudent for public company legal departments to consider all aspects of the annual board independence process, including the questionnaire forms used, to better assist boards in discharging this important annual duty.

    Authors

    Thomas P. Conaghan

    Partner

    Washington, DC, New York – One Vanderbilt Avenue

    Eric Orsic

    Partner

    Chicago

    Paul M.G. Helms

    Partner

    Chicago, Washington, DC

    Daniel L. Woodard

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • Jarrett 2.0: Taxpayer Files New Lawsuit on Crypto Staking Tax Treatment

    Jarrett 2.0: Taxpayer Files New Lawsuit on Crypto Staking Tax Treatment

    ARTICLE / CLIENT ALERT

    Jarrett 2.0: Taxpayer Files New Lawsuit on Crypto Staking Tax Treatment

    October 15, 2024

    Read time: 5 min

    Key takeaways
    Overview

    On October 10, 2024, Joshua and Jessica Jarrett filed a complaint against the United States asserting that cryptocurrency tokens created through staking are new property and should not be treated as income. Jarrett, et al. v. United States of America, Docket No. 3:24-cv-01209 (M.D. Tenn. Oct. 10, 2024). This position challenges Internal Revenue Service (IRS) Revenue Ruling 2023-14, which concludes that staking rewards are includible in a taxpayer’s gross income in the tax year in which the taxpayer gains “dominion and control” over the staking rewards.

    In this article, we consider the tax implications arising from this case, which may impact taxpayers who are engaged in crypto staking activities.

    In depth

    Background

    For those that have been following recent developments in the taxation of crypto and crypto staking, the Jarretts may seem familiar. Last year, the same couple argued before the US Court of Appeals for the Sixth Circuit regarding the same issue: whether the receipt of staking rewards generates taxable income at the date the rewards are received.

    Jarrett initially sued the IRS in 2022 for a refund in connection with his 2019 tax year, claiming that he overpaid his 2019 taxes because his payment included amounts for taxes arising in connection with the creation of certain Tezos crypto tokens. Jarrett v. United States, No. 3:21-cv-00419, 2022 BL 349876 (M.D. Tenn. Sept. 30, 2022). Jarrett argued that the tax was inappropriate because he had created new tokens by staking existing tokens that he owned. Accordingly, he should have owed tax on the tokens only upon sale or transfer, rather than upon creation. Before the parties reached oral argument, the government granted Jarrett’s refund request and directed the IRS to schedule an overpayment. The government then moved to dismiss the case (claiming that the full refund resolved the dispute), which the district court sustained.

    Refusing to accept or cash the refund check, Jarrett appealed to the Sixth Circuit, claiming that the refund claim remained a live dispute. Jarrett v. United States, No. 22-6023 (6th Cir. 2023). While it did not impact the Sixth Circuit’s decision, the IRS formalized its position on the taxation of staking rewards shortly after oral arguments were completed, releasing Revenue Ruling 2023-14. The Sixth Circuit affirmed the district court’s ruling, concluding that the IRS refund check mooted the prior case.

    Treating Tokens Created From Staking as New Property

    Last week’s complaint (now relating to Jarrett’s 2020 tax year) features similar facts to the prior case and takes a similar tax position on staking rewards. Jarrett created new Tezos tokens in 2020 by staking his existing Tezos tokens. The complaint contends that the newly created tokens should be treated as new property and, under the realization requirement, should not be taxable as income until transferred or otherwise disposed of. The complaint also provides various illustrative analogies between the new tokens and other forms of new property that are not taxed upon receipt, including comparisons to vegetables grown by farmers, manuscripts drafted by Stephen King, and widgets manufactured in a factory (highlighting that in each case such property is not subject to tax until sold).

    In addition to the realization requirement, the complaint also discusses the dilutive effect of the staking rewards, asserting that the creation of new tokens also offsets the economic gain from the newly created tokens to the extent that the new tokens diminish the value of existing tokens. This is highlighted in the comparison between staking rewards and stock received pursuant to a stock split. Accordingly, the complaint contends that the taxation of the new tokens would result in overtaxation to the extent that the new tokens diluted the value of the existing tokens.

    The Jarretts have requested several forms of relief from the district court. Among other requests, the Jarretts have requested that the district court grant a judgment that the disputed federal income taxes were erroneously assessed, an order awarding a refund for amounts paid for their 2020 tax year, and a permanent injunction against the IRS preventing it from treating tokens created by the Jarretts as income.

    Conclusion

    Because the US previously chose to refund the applicable taxes to the Jarretts rather than litigating to a dispositive decision, this case presents the Jarretts with a second chance to challenge the IRS’ published position regarding the taxation of staking rewards. Of course, revenue rulings generally represent the IRS’ interpretation of existing tax law and are not binding on the courts. Accordingly, a ruling in Jarrett’s favor may drastically alter the taxation of crypto staking rewards and could even result in deferred taxation on tokens rewarded in connection with taxpayer staking activities. We expect this case will be closely followed by taxpayers engaged in crypto staking activities.

    If you have questions about the tax implications of staking activities, please contact the authors of this article or your regular McDermott contact(s).

    Authors

    John T. Lutz

    Partner

    New York – One Vanderbilt Avenue

    Andrew M. Granek

    Partner

    New York – One Vanderbilt Avenue

    Anthony Teng

    Associate

    New York – One Vanderbilt Avenue

    More insights

  • New Premerger Notification Regime to Fundamentally Change M&A Strategy

    New Premerger Notification Regime to Fundamentally Change M&A Strategy

    ARTICLE / CLIENT ALERT

    New Premerger Notification Regime to Fundamentally Change M&A Strategy

    October 14, 2024

    Read time: 14 min

    Key takeaways
    Overview

    On October 10, 2024, the Federal Trade Commission (FTC) voted 5-0 to issue new final rules (Rules) governing the US premerger notification filing process. These Rules – the first major overhaul to the Hart-Scott-Rodino (HSR) filing form in the nearly 50-year history of the HSR Act – will fundamentally alter the premerger notification process. While the Rules omit some of the more extreme aspects proposed in the 2023 draft rules, such as the need to provide draft documents and labor data, they impose substantially more burdens on filing parties than the current filing regime. The changes will have wide-ranging implications for all parties required to notify transactions under the HSR Act.

    In depth

    The overall process will be more burdensome and time-consuming to complete. The Rules not only require significantly more information, data, and documents as part of the initial filing, but they also require merging parties to evaluate and present written descriptions on transaction rationale, competitive overlaps, and/or vertical relationships with the initial filing. This will force merging parties to address substantive antitrust issues earlier in the process, even for those transactions that might raise marginal antitrust issues. Importantly, with the initial HSR filing, the FTC and US Department of Justice (collectively, the Agencies) will now receive ordinary course planning documents and more transaction documents – materials that they currently seek via a Second Request or voluntary access letter. Thus, some of the work that previously was deferred and only done if the Agencies investigated now needs to be done up front to have a compliant and compelling filing.

    While changes associated with the Rules will be most significant for transactions that may raise horizonal, vertical, or potential competition issues, changes will also be felt in any transaction subject to HSR reporting.[1] Companies that are active in mergers and acquisitions (M&A) should start work now to update their standby information for the premerger notification process to alleviate some of the burden when the Rules take effect.

    The Agencies’ stated rationale for these changes is to facilitate a more comprehensive and accurate antitrust assessment at the early stages of a transaction. As a result, the Agencies have agreed to reinstate discretionary grants of early termination, which facilitate a transaction closing prior to the expiry of the full waiting period.

    The Rules will likely go into effect and apply to transactions filed in mid-January 2025 (90 days after the notice is published in the Federal Register). Below, we explore the most notable changes to the HSR filing requirements and implications for companies engaged in transactions subject to the HSR Act.

    Changes Impact the Substantive Review of Many Transactions

    Some changes in the Rules are updates to existing requirements; others are brand new. These new obligations will significantly impact both the filing process and broader M&A planning and strategy. The most significant substantive changes require (i) written descriptions of the transaction rationale and of any product overlaps or vertical relationships, with accompanying sales and customer data, and (ii) the submission of more transaction-related documents, as well as certain ordinary course materials regarding overlapping products. Collectively, these changes will require additional work to formulate and submit antitrust arguments for any transaction involving a horizontal overlap or plausible vertical theory. Contrary to current practice in many deals, substance will now need to be addressed in the filing.

    Written Descriptions

    The Agencies believe up-front narrative responses will give them a more complete basis to assess a transaction’s potential competitive effects and to decide whether to investigate a deal further.

    • Transaction Rationale: Filing persons must provide a description that identifies and explains each strategic rationale considered at any point for the transaction and identify documents submitted with the HSR filing that support the submitted rationale(s).
    • Competition Analysis: Filing persons must describe their general business lines, including product or service lines of all related entities, and current and potential future horizontal overlaps and supply relationships between the filing parties. For each overlapping product or service, the filer must provide sales information, a description of categories of customers, and a list of the top 10 customers for each category. For supply relationships, the acquiring entity must provide information about sales to or purchases from the target or any business that competes with the target, as well as the top 10 customers or suppliers, with a description of the contract or terms of sale.

    Parties Must Submit More Documents to the Agencies With Their Filings

    Filers will now have to submit ordinary course planning documents related to overlapping products, as well as more extensive transaction-related documents. This new requirement will enable the Agencies to obtain a company’s most sensitive business documents at the outset of their investigation, even if a transaction does not raise substantive concerns.

    • Submission of Certain Ordinary Course and Strategic Documents: The Rules require filing persons to submit high-level business documents that were not created in contemplation of or preparation for the transaction but that touch on competitive issues for any overlapping product or service.
      • Reports Provided to the CEO: Parties must provide all annual, semiannual, or quarterly plans and reports prepared or modified within one year of the date of filing that were provided to the CEO, which analyze market shares, competition, competitors, or markets for any current or future overlap product or service.
      • Reports Provided to the Board: The same types of competition documents provided to the Board within the past year also need to be provided, regardless of the timing or cadence of presentation. Although the Rules eliminated the initial proposal to include all drafts of transaction documents, the Rules contemplate that certain drafts shared with a member of the Board may need to be produced in some circumstances.
    • Transaction Documents From a Non-Officer Transaction Lead: The Rules expand the range and volume of transaction-related documents required. Today, parties submit only final documents (or the most recent draft if not final) prepared by or for a party’s officers or directors, evaluating the transaction with respect to markets, market shares, competition, competitors, potential for sales growth or expansion, or synergies (known as Item 4 documents). The new Rules define these documents the same but now require the filer to collect them from a “supervisory deal team lead” in addition to officers and directors. The supervisory deal team lead is defined as the “individual who has primary responsibility for supervising the strategic assessment of the deal, and who would not otherwise qualify as an officer or director.” Providing documents from a lower-level employee who is involved in the daily back and forth of a transaction has the potential to increase the volume of materials to be searched and produced.

    Additional Changes to Reporting Requirements Will Increase Filing Burdens

    Below, we highlight other key changes to the HSR reporting requirements. While these changes are unlikely to impact the substantive review of most filings, they will create additional procedural burdens and require new workstreams for HSR filers.

    • Filing on Letters of Intent Have Additional Requirements: The Rules will continue to allow merging parties to file on the basis of preliminary agreements (e.g., indication of interest, letter of intent, or agreement in principle) but will require that the documents include a detailed description of the transaction’s key terms, including “some combination of” the identity of the parties; the structure of the transaction; the scope of what is being acquired; calculation of the purchase price; an estimated closing timeline; employee retention policies, including with respect to key personnel; post-closing governance; and transaction expenses or other material terms. If this information is not included in the preliminary agreement, parties will need to submit a dated document such as a term sheet or draft definitive agreement with these details.
    • Activities of Officers and Directors: The Agencies will now receive more information related to situations in which the officers and directors of entities the HSR filer controls serve in a similar role on another firm active in the same industry as the target. Specifically, the acquiring person must identify all persons who serve as officers or directors of (i) all entities within the acquiring person that operate in the same industry as the target or (ii) the acquiring entity or any entities it controls or that control it, including those persons likely to take on such a role as a result of the transaction at issue, and who, in the case of both (i) and (ii) above also serve as an officer or director of another entity outside of the acquiror’s organization that operates in the same industry as the target (excluding charitable and not-for-profit entities).
    • Prior Acquisitions: The Rules now require both the acquiring person and the target to report prior acquisitions in overlapping areas that occurred within five years of the filing, purportedly to allow the Agencies to consider the competitive effects of a transaction in the context of other acquisitions (e.g., roll up strategies). There is a $10 million de minimis threshold for relevant prior acquisitions.
    • Minority Interest Holders: In a change likely to impact private equity funds, the Rules now require reporting of minority interest holders anywhere in an acquiring entity’s corporate chain. The acquiring person needs to identify minority interest holders (5% or more but less than 50%) not only of the acquiring entity (as is the case currently) but also of entities directly or indirectly controlled by the acquiring entity or that directly or indirectly control the acquiring entity. If the interest holder is a limited partner, that person will need to be identified if they have the right to influence the Board of the entity in which they hold an interest, such as by having the right to appoint or nominate a member. Previously, filers only needed to list the general partner of a limited partnership.
    • Geographic Information: The Rules updated the list of North American Industry Classification System (NAICS) codes for which location information need only be reported at the state level and NAICS codes for which street-level information is required. The Rules add a requirement to list locations where franchisees generate revenue in overlapping NAICS codes that require street-level location information.
    • Streamlined Approach to Reporting Revenues: The Rules reduce the compliance burden by (i) eliminating the requirement to report the precise amount of revenue to each NAICS code, instead simply requiring an estimation into one of five buckets and (ii) eliminating the need to further break down manufacturing revenues into 10-digit NAPCS codes. The Rules, however, add a requirement for filing parties to indicate which of its operating entities derive revenues in each NAICS code.
    • Defense and Intelligence Community Procurement Contracts: The Rules add a requirement to report existing or pending contracts with the US Department of Defense or the intelligence community where the contract is valued at $100 million or more and involves a product or service identified in the narrative description of the overlapping or supply relationships. For such contracts, filers must provide identifying information. Filings must also indicate if responsive classified information has been omitted from the HSR form.
    • Foreign Subsidies: The Agencies believe the existence of subsidies from certain foreign countries (e.g., China, Russia, North Korea, or Iran) or entities can influence incentives or distort the competitive process. The new Rules seek to gather information related to those foreign financial relationships.
    • Minor Changes to Pull and Refile Process: Where an acquiring person pulls and refiles an HSR filing, the Rules will require them to submit newly created transaction related documents, updated transaction agreements, and updated information about foreign subsidies.

    Practical Implications of HSR Rule Changes on M&A Strategy and Antitrust Clearance

    The Rules do much more than change the HSR form: They will fundamentally change business and M&A strategy. Here’s how companies should adapt:

    • Early Antitrust Assessment Is Critical. The Rules make early antitrust analysis critical for nearly all HSR-reportable transactions. It will no longer be sufficient to make an HSR filing and figure the substance out later.

    Further, while the FTC states that the new transaction and competitive analysis descriptions should be brief and can be prepared by business personnel, the descriptions will play an important role in determining whether the Agencies initiate a merger investigation and will be critical to parties’ success once an investigation has been opened. These descriptions are the first opportunity to dissuade the Agencies from investigating a transaction, or to narrow the issues that will be investigated. For transactions involving horizontal or vertical overlaps, the stakes will be especially high, since the filers’ initial positions are likely to be pressure tested throughout the investigation process. All this means that the descriptions parties submit must be correct and must be consistent with internal business documents. Getting it right means investigating and exploring the facts on the ground and fashioning measured, well-considered substantive descriptions with the assistance of antitrust counsel.

    • Document Creation Discipline Is Key. It is more important than ever for companies to pay attention to document creation. The Rules will require transacting parties to submit more documents, sometimes from employees with lower seniority levels, than in the past. That gives the Agencies more opportunities to find substantive concerns with a transaction that warrant further investigation. To limit this risk, companies should introduce or enhance antitrust training regarding document creation. This training should reach the kinds of employees likely to create (i) the ordinary course strategic and business planning documents and (ii) the expanded universe of transaction-related documents called for by the Rules. Substantively, training should help employees understand how the Agencies may interpret what they draft and share. Companies that anticipate a reportable deal should identify potential “supervisory deal team leads” and put them in contact with the legal team to evaluate and develop deal-specific themes early in the transaction evaluation process. These personnel should be well trained to coordinate closely with legal counsel throughout the deal process.

    Personnel involved in ordinary course business reporting to executives and the Board should coordinate closely with the legal team and provide the legal team with an opportunity to review and advise on draft documents. Under some circumstances, companies may want to conduct periodic audits of documents to evaluate current document creation practices and to provide targeted feedback. Strategic documents about product or service lines, markets, or competition should be accurate and based on actual data or facts. And less is more: Authors should learn to minimize any content that could be misconstrued in a way that could be harmful for competition reviews (e.g., descriptions of overly narrow product and geographic market definitions, exaggerated barriers to entry, or diminished importance of categories of competitors). Additionally, companies active in M&A should avoid creating acquisition pipeline documents that discuss multiple transactions in the same document. Companies may also want to evaluate the scope of strategy and business planning documents that are provided to their Board, as these documents now may need to be produced with the initial filing.

    • HSR Process Will Begin Well in Advance of Signing a Definitive Agreement. The new HSR form will take substantial additional time to prepare. Competent filers will address substantive issues earlier in the process to craft key themes for required narrative descriptions addressing deal rationales, relationships between the transacting parties, and competition analyses. For frequent HSR filers, being prepared to make speedy filings will mean creating more off-the-shelf items for use in future HSR filings. Many parties already do this with revenue and subsidiary information and could maintain efficiency by expanding their preparation efforts to cover information about principal product and service lines, officers and directors, past transactions, foreign subsidies, and defense-industry contracts.
    • Transaction Agreements Should Provide Filing Flexibility. Going forward, transaction agreements must be built to accommodate a more time-consuming HSR process, including newly time-consuming information requests, the need to make strategic determinations regarding the competition and overlap analysis, and coordination with counterparty counsel. For transactions being explored or negotiated in the fall of 2024, parties may want to include “provisional” terms to cover deals in which a filing date can be set if it is filed under the current rules, along with a more flexible standard should the filing occur under the new Rules.
    • The Rules Could Impact Substantive Agency Review. While the Rules are procedural and not designed to change substantive antitrust law, they could impact the likelihood that a given transaction will be subjected to an extended review through the issuance of a Second Request. It is possible that some transactions will not elicit a lengthy review if the written descriptions and documents convincingly explain that the transaction will not harm competition. It is also possible that other transactions, which may not have attracted a substantive review under the old rules, may attract more interest if not properly described in the initial HSR filing.

    In sum, the Rules usher in a new world. They change the HSR process, implicating more information and more people than in the past. These changes, in turn, change the way merging parties must approach antitrust issues in their deals.

    McDermott’s antitrust team will be presenting a webinar on October 29, 2024, to explain these changes and discuss their implications for your business. If you have questions about the Rules or how to educate your team on the implications, please contact your regular McDermott lawyer or the authors of this article.

    Authors

    Jon B. Dubrow

    Partner

    Washington, DC

    Raymond A. Jacobsen , Jr.

    Partner

    Washington, DC

    Lisa P. Rumin

    Partner

    Washington, DC

    Ryan C. Tisch

    Partner

    Washington, DC

    Noah Feldman Greene

    Partner

    Washington, DC

    Graham J. Hyman

    Associate

    New York – One Vanderbilt Avenue

    More insights

  • MHRA Updates its Timeline for Medical Device Regulatory Changes in the UK

    MHRA Updates its Timeline for Medical Device Regulatory Changes in the UK

    ARTICLE / CLIENT ALERT

    MHRA Updates its Timeline for Medical Device Regulatory Changes in the UK

    October 14, 2024

    Read time: 4 min

    Key takeaways
    Overview

    The MHRA recently published an update on its plans for MedTech regulatory change. The update confirmed that the new framework will be introduced through four statutory instruments to update and replace the UK Medical Devices Regulations 2002. The UK government has confirmed that a statutory instrument, which will set out new rules for Post Market Surveillance (PMS) which will strengthen requirements for vigilance and surveillance of products on the market is expected to be laid in Parliament before the end of 2024.

    But the timing for most important changes, described as the “core regulations” or “Pre-Market SI”, and which will include the bulk of updates to the UK MDR is still unclear. According to the MHRA RoadMap published in January 2024, these core regulations were intended to be laid in mid-2025. Given the delay, it is possible that this date may now be later.

    After the PMS SI, the MHRA plans to consult later in 2024 about the content of the “Pre-Market SI” but has said that:

    • The changes “will be in line with” the 2021 consultation, the response to which was published in 2022. The 2021 consultation proposed:
      • Up-classing of devices similar to those contained in the EU MDR and EU in vitro diagnostic regulations (EU IVDR);
      • Transitional arrangement for these products to allow, at a minimum, products to be placed on the market until either the certificate expires or for three years after the new regulations take effect (in the case of general medical devices) or five years (in the case of IVDs);
      • Assignment of unique device identifiers for certain medical devices, such as implantables; and
      • New requirements about the claims made about devices by manufacturers.
    • The 2024 consultation will include more detailed and focused proposals about longer term international recognition.
    • The adoption of a risk stratification approach for IVDs, adopting the International Medical Device Regulators Forum approach of an A-D classification. Of interest, is that the MHRA has indicated that most class B devices will be able to self-assess conformity with the regulations. Under the EU IVDR, only class A IVDs may be self-assessed.

    The MHRA has said that its ambition is to complete this consultation by the end of 2024. This timetable appears somewhat ambitious. By way of example, the 2021 consultation was 10 weeks long – so, for the MHRA to meet its ambition, the consultation will likely need to be published before the end of October 2024.

    The implementation of the Pre-Market SI is also unclear. There are several steps which need to happen before the regulations can be implemented, including notification of the World Trade Organisation, which must publish the draft regulations for a period of at least 60 days for comment before the regulations can be laid in the UK Parliament.

    The MedTech industry is closely monitoring these changes.

    On 10 October 2024 the Association of British Healthtech and CPI published the 2024 Pulse of the Sector Survey Report which highlighted the continuing challenges about regulatory uncertainty in the UK market with more than 82% of the industry indicating that they had been affected in some way by the lack of clarity. Alongside regulatory uncertainty, the NHS Net Zero Roadmap was also raised as an unattractive factor for the sector.  Despite these issues, the report still indicated optimism with over 30% of companies planning to expand R&D and manufacturing in the UK and many describing the UK as a research-friendly environment.

    In depth
    Authors

    Sharon Lamb

    Partner

    London – 22 Bishopsgate

    Bella North

    Senior Associate

    London – 22 Bishopsgate

    More insights

  • Back-to-School Special: IRS Offers Insight Into Matching Qualified Student Loan Payments

    Back-to-School Special: IRS Offers Insight Into Matching Qualified Student Loan Payments

    ARTICLE / CLIENT ALERT

    Back-to-School Special: IRS Offers Insight Into Matching Qualified Student Loan Payments

    October 10, 2024

    Read time: 6 min

    Key takeaways
    Overview

    On August 19, 2024, the Internal Revenue Service (IRS) issued Notice 2024-63 (the Notice), providing guidance regarding the implementation of Section 110 of the SECURE 2.0 Act of 2022 (SECURE 2.0), which permits employers with a 401(k) plan or 403(b) plan to provide matching contributions to employees based on employee student loan payments. Through various questions and answers, the Notice provides practical information on how to administer eligibility rules, employee certification, nondiscrimination testing, and other procedures.

    In depth

    Key Takeaways From Notice 2024-63

    Eligibility for Student Loan Matching Contributions: The Notice begins by defining what a qualified student loan payment (QSLP) is and clarifying who can make a QLSP.

    A QSLP is a payment made by an employee during a plan year in repayment of a qualified education loan incurred by the employee to pay for qualified higher education expenses of the employee, the employee’s spouse, or the employee’s dependent. For a student loan to be considered incurred by the employee, the employee must have a legal obligation to make payments under the terms of the loan. Notably, the Notice distinguishes between a co-signer who has such an obligation (eligible) and a guarantor who would only have an obligation if the primary borrower defaults (ineligible).

    The Notice also explains that QSLP matching contributions cannot be limited to loans for a particular degree program (e.g., Bachelor of Arts) or attendance at a particular school. As for employee eligibility, all employees eligible to receive “regular” matching contributions based on elective deferrals under a plan must be eligible to receive QSLP matching contributions. Likewise, all employees eligible to receive QSLP matching contributions must also be eligible to receive regular matching contributions based on elective deferrals. However, an employer may exclude collectively bargained employees from QSLP matching contributions.

    Limits: The Notice clarifies the qualified plan limits that apply to QSLP matching contribution amounts. An employee’s loan payments can only be QSLPs to the extent that such aggregated payments for a year do not exceed the Section 402(g) limit of the Internal Revenue Code (the Code) ($23,000 in 2024) minus the amount of the employee’s elective deferrals for the year (or, if lesser, the employee’s compensation under the Section 415(c)(3) limit of the Code, reduced by the employee’s elective deferrals for the year). The Notice also clarifies that only QSLPs made during a plan year are eligible for purposes of determining the amount of a QSLP matching contribution.

    Employee Certification: The Notice offers plan administrators flexibility to attain employee certification. Plan administrators must obtain certification of specific information regarding a QSLP, including (1) the amount of the loan payment; (2) the date(s) of the loan payment; (3) confirmation the payment(s) was made by the employee; (4) confirmation the loan is for a qualified educational loan for the employee, the employee’s spouse, or the employee’s dependent; and (5) that the loan was incurred by the employee (meaning that not only did the employee make the payment, but he or she also had an obligation to do so).

    The certification requirement can be satisfied in various ways, including through either affirmative certification by the employee or, for items (1) through (3) above, “passive” certification. (The affirmative employee certification requirement always applies to items (4) and (5).) For example, an employer may require employees to register the qualified loan with a third-party service provider. Registration with a third-party service provider would affirmatively satisfy verification of items (4) and (5). The third-party service provider would receive information about items (1) and (2). The employer may then notify the employee of this information received from the third-party service provider, along with a statement that the employer is assuming item (3) is also satisfied. If the employee does not correct the information within a reasonable time period, then items (1) through (3) are “passively” certified. Items (1) through (3) must be certified annually, though the employer has until to 2.5 months after the end of the plan year to do so. Items (4) and (5) need only be certified once for each loan. Employees do not need to submit additional documentation to support certification that the qualified loan payment meets the requirements of an QSLP.

    QSLP Match Procedures: The Notice gives employers permission to establish reasonable procedures to implement the QSLP matching contribution. A plan may provide for QSLP matching contributions at a different frequency than its elective deferral matching contributions. For example, if the employer’s plan makes elective deferral matching contributions on a per-pay-period basis, QSLP matching contributions can be done on an annual, quarterly, or rolling basis. A plan can establish a single claims deadline or multiple claims deadlines for the QSLP matching contribution for a year as long as the deadlines are reasonable.

    Corrections: If a plan administrator later learns that an employee’s certification of a QSLP was incorrect, a matching contribution based on that incorrect certification does not need to be corrected (although correction is permissible if all QSLP matches made under similar incorrect circumstances are corrected). However, to the extent a plan has an operational failure in administering the QSLP match, the IRS expects that the operational failure would be corrected.

    ADP Testing/Safe Harbor Plan Options: A plan with a QSLP matching contribution can choose to test all employees together or separately test employees who receive a QSLP matching contribution for actual deferral percentage (ADP) testing purposes. With respect to safe harbor plans, a QSLP matching contribution may be added as a mid-year change. However, the notice and election opportunity requirements for mid-year changes to safe harbor plans still apply. An updated safe harbor notice that describes the mid-year change (e.g., implementation of a QSLP matching contribution) must be sent to employees 30 to 90 days before the effective date of the change. Each employee must also be given a reasonable opportunity (e.g., a 30-day election period) before the effective date to change their deferral elections.

    Next Steps

    The Notice applies for plan years beginning after December 31, 2024, and is subject to comment for a period of 60 days. The IRS indicated that it will eventually issue proposed regulations with further guidance on Section 110 of SECURE 2.0. Until then, employers can rely on the Notice. For periods prior to the Notice effective date, employers can rely on their good faith interpretation.

    Authors

    Jeffrey M. Holdvogt

    Partner

    Chicago

    More insights

  • Tirzepatide Shortage Resolved

    Tirzepatide Shortage Resolved

    ARTICLE / CLIENT ALERT

    Tirzepatide Shortage Resolved

    October 9, 2024

    Read time: 5 min

    Key takeaways
    Overview

    On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 (GLP-1) medication, marking the shortage as “resolved” for all presentations of the drug. An end to the shortage has important implications for industry stakeholders at various points in the medication’s supply chain. Compounding pharmacies and providers should be aware of the impact this change in shortage status has on their operations. We discussed the potential effects of a resolution of the shortage in our previous On the Subject entitled “Weight Loss Drug Shortages Will End Soon.”

    Update: On October 11, 2024, FDA agreed to reconsider its decision to remove tirzepatide from its drug shortage list in response to the complaint filed by the Outsourcing Facilities Association (OFA) and North American Custom Laboratories, LLC, doing business as FarmaKeio Custom Compounding. The litigation is stayed and tirzepatide remains off the shortage list while FDA reviews its decision (although FDA has indicated it will not take enforcement actions against the plaintiffs). Additionally, following FDA’s October 3 decision, several Congress members sent a letter to the agency encouraging the utilization of data from compounding facilities to help avoid and mitigate drug shortages. The letter also raises specific concerns about the data FDA reviews in establishing the list, urging the agency to review data outside of that which was submitted by the drug manufacturer.

    Update: On November 21, 2024, the parties submitted a joint status report stating that the case should remain stayed while FDA continues to evaluate its decision to remove tirzepatide from the shortage list. The parties intend to file a further joint status report by the earlier of December 19, 2024, or within seven days of FDA’s decision on remand. Accordingly, FDA will continue to refrain from enforcement actions against essentially copies of tirzepatide until further notice.

    Update: On December 19, 2024, the FDA issued a Declaratory Order confirming FDA’s October decision to remove tirzepatide from the shortage list. FDA stated it has completed its reevaluation of its decision and determined that the information and data provided by the brand manufacturer demonstrate the supply is currently meeting or exceeding demand for tirzepatide. In its Order, FDA extended its enforcement discretion for 503A pharmacies for 60 calendar days from the date of the Order (i.e., until February 18, 2025) and for 503B outsourcing facilities for 90 calendar days (i.e., until March 19, 2025). The litigation filed by the Outsourcing Facilities Association remains ongoing.

    In depth

    This October revision updates FDA’s August partial revision of the availabilities for certain semaglutide and tirzepatide presentations. The FDA’s shortage list maintains the status of semaglutide as “currently in shortage,” although only one presentation – Wegovy 0.25 mg/0.5 mL – is marked for limited availability. Other GLP-1 medication active pharmaceutical ingredients, such as liraglutide, remain listed as “limited availability” in the drug shortage database. As anticipated, the national shortage of certain GLP-1 medications appears to be coming to an end.

    503A compounding pharmacies will generally no longer be able to rely on the FDA shortage list exception for compounding “essentially copies” of tirzepatide products. This means that in order to regularly compound tirzepatide products (i.e., to fulfill five or more such products per calendar month), compounding pharmacies must ensure that compounded tirzepatide products do not contain the same, similar, or easily substitutable dosage strength, or that such products are not used by the same route of administration as the commercially available product. Otherwise, there must be some other change that a prescriber determines produces a significant difference for the individual patient, documented on the prescription. FDA’s guidance “Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act” indicates that changes fitting that criterion (although we note that such changes are not necessarily applicable to GLP-1 drugs) may include the removal of inactive ingredients due to patient allergy, or change from tablet to liquid form due to patient inability to swallow tablets.

    For 503B compounding, outsourcing facilities may continue to dispense essentially copies of compounded tirzepatide products for orders the facility received prior to the shortage resolution for up to 60 days from when tirzepatide was removed from the shortage list (i.e., until December 2, 2024). 503B outsourcing facilities thus have a 60-day sell-through period to fulfill orders for tirzepatide that were received before October 3, 2024. 503B facilities may not compound tirzepatide products for orders received on or after October 3, 2024, and must cease distribution by December 2, 2024. 503B facilities may continue to compound and dispense tirzepatide products that are not essentially copies, as described above.

    This change is not without controversy. On October 7, 2024, the OFA and North American Custom Laboratories, doing business as FarmaKeio Custom Compounding, filed a complaint in the US District Court for the Northern District of Texas alleging that FDA’s revision of tirzepatide availability constitutes a final agency action that is arbitrary, capricious, and contrary to law. The complaint cites to Loper Bright, the recent US Supreme Court decision overturning Chevron deference, as support for rejecting FDA’s interpretation of its statutory authority to maintain the shortage list.

    We will continue to monitor this litigation, the shortage status of GLP-1 medications, and the impact on the industry.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Paul S. Gadiock

    Partner

    San Francisco

    Marshall E. Jackson , Jr.

    Partner

    Washington, DC

    Lisa Mazur

    Partner

    Chicago

    Patrick Zanayed

    Partner

    Chicago

    Paul W. Hughes

    Partner

    Washington, DC

    Jae Hyun Lee

    Associate

    New York – One Vanderbilt Avenue

    More insights

  • New Duty on UK Employers to Prevent Sexual Harassment

    New Duty on UK Employers to Prevent Sexual Harassment

    ARTICLE / CLIENT ALERT

    New Duty on UK Employers to Prevent Sexual Harassment

    October 9, 2024

    Read time: 6 min

    Key takeaways
    Overview

    From 26 October 2024, UK employers will be subject to a new positive duty to prevent sexual harassment of workers in the course of their employment. The new preventative duty is set out in the Worker Protection (Amendment of Equality Act 2010) Act 2023 (the Act).

    In anticipation of the new law coming into force, the UK Equality and Human Rights Commission has recently published updated Technical Guidance on “Sexual harassment and harassment at work” intended to help employers understand their new obligations. The guidance has also been supplemented by an “Employer 8-step guide”. Whilst the technical guidance and step plan is not legally binding in and of itself, it is likely that employment tribunals will have regard to these in practice when assessing whether or not an employer has met the new legal duty.

    The preventative duty cannot be enforced by workers directly on a standalone basis. In the event of a successful harassment claim involving some form of sexual harassment, however, an employer who is found to have breached the preventative duty could be liable to an uplift of up to an additional 25% of the compensation award. It remains the case the potential amount of compensation awardable in a successful harassment claim is not subject to any cap. The EHRC also has the power to conduct investigations and take enforcement against employers, irrespective of whether any complaint has been brought.

    In depth

    What is Changing?

    Under existing UK anti-discrimination and harassment laws, a UK employer will be held vicariously liable for acts of discrimination, victimisation or harassment committed by workers in the course of employment unless they can show that they took “all reasonable steps” to prevent those acts. Those longstanding existing laws will continue to apply.

    The Act introduces a new positive legal duty on employers to take reasonable steps to prevent sexual harassment of their workers. It has been designed to improve workplace cultures by requiring employers to anticipate how sexual harassment might happen in their workplace and take proactive reasonable steps to prevent it happening, rather than focussing on harassment in a more reactive way. Notably, the preventative duty applies not just to worker-on-worker sexual harassment, but also sexual harassment by third parties such as customers, clients or patients.

    What Forms of Harassment Does the New Duty Apply To?

    The new preventative duty applies only to sexual harassment.

    Under the UK Equality Act 2010, sexual harassment is defined as “unwanted conduct of a sexual nature which has the purpose or effect of violating someone’s dignity or creating an intimidating, hostile, degrading, humiliating or offensive environment for them”.

    It does not, therefore, cover harassment related to a protected characteristic (including sex), nor does it apply to less favourable treatment for rejecting or submitting to unwanted conduct. However, those types of harassment nevertheless remain unlawful and it is expected that employers should continue to take steps to prevent all types of harassment at work or else risk being found vicariously liable for any unlawful acts.

    What Steps Should UK Employers be Taking?

    The Act does not specify what constitutes “reasonable steps”.

    The EHRC’s Technical Guidance, whilst describing a wide range of measures that employers could potentially take to prevent sexual harassment, also makes clear that what is reasonable will ultimately vary from employer to employer, including depending on the size and nature of the employer, the resources available to it and the risks factors which need to be addressed within a particular employer or sector.

    To assist employers’ in their compliance efforts, however, the EHRC has also recently published an ‘Employer 8-step guide’, which recommends that UK employers take the following (non-exhaustive) steps:

    1. Develop an effective anti-harassment policy that deals with sexual harassment (whether as a standalone policy or together with other forms of harassment).
    2. Engage with staff. This includes conducting regular one to ones, running staff surveys, conducting exit interviews and having open door policies.
    3. Carry out risk assessments and taking steps to reduce workplace risks identified. This will include considering factors that might increase the likelihood of sexual harassment and the steps that can be taken to minimise them. For instance, identifying power imbalances, instances of lone working, external events, conferences or training, general workforce culture, staff socialising and the prevalence of customers or staff drinking alcohol.
    4. Implementing a reporting system (such as an online or independent telephone-based service) that allows workers to raise an issue either anonymously or in name. Keeping centralised, confidential records of all concerns raised, formal and informal, that enables trends to be identified. 
    5. Training. All staff should be trained on sexual harassment in the workplace, including what it looks like, what to do if they experience or witness it and how to handle any complaints of harassment. In industries where third-party harassment from customers is more likely, workers should also be trained on how to address these issues.
    6. Act immediately to resolve complaints and protect the complainant from ongoing harassment or being victimised during an investigation or complaint. Employers should, of course, also respect the confidentiality of all parties.
    7. Address harassment by third parties, such as customers, clients, patients or suppliers just as seriously as that by a colleague and consider what steps can be taken to prevent this type of harssment.
    8. Continue to monitor and evaluate the effectiveness of steps put in place to prevent sexual harassment. This final point underscores the fact that compliance with the new preventative duty requires ongoing consideration, including on account of changes in the workforce and feedback from workers or their representatives.
    Authors
    More insights